Graft antigens trigger tumor immunity

Ovarian grafts may help the body spot early cancers, rather than simply restore hormones. This hypothesis asks whether young ovarian tissue can act like a tumor vaccine. Removing germ cells, which make eggs, might expose antigens, molecular features recognized by immunity, shared with developing tumors. Immune cells could cross-present them to tumor-reactive T cells, white blood cells that attack matching targets. Before a lifespan study, shared antigens and tumor recognition must be demonstrated in the recipient strain. Protection transferred by purified T cells, but absent from donor-free serum, would support tumor-specific immunity. If dying donor cells also produce protection, clearance of cell debris and inflammation becomes a stronger rival.